Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.66 EUR | +3.59% | +4.84% | +82.32% |
04-05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
03-28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.07M 54.86M 4.39B | Sales 2025 * | 58.83M 63.21M 5.06B | Capitalization | 72.14M 77.5M 6.21B |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M 86.03M | Net income 2025 * | 3M 3.22M 258M | EV / Sales 2024 * | 1.19 x |
Net cash position 2024 * | 11.27M 12.1M 969M | Net cash position 2025 * | 12M 12.89M 1.03B | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
72.2
x | P/E ratio 2025 * |
20
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | +3.59% | ||
1 week | +4.84% | ||
Current month | +4.84% | ||
1 month | +11.03% | ||
3 months | +55.20% | ||
6 months | +158.51% | ||
Current year | +82.32% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 31/12/21 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 31/12/20 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 31/12/20 |
Chairman | 51 | 31/12/20 |
Date | Price | Change | Volume |
---|---|---|---|
08/05/24 | 8.66 | +3.59% | 3,790 |
07/05/24 | 8.36 | +1.21% | 3,824 |
06/05/24 | 8.26 | 0.00% | 102 |
03/05/24 | 8.26 | -0.24% | 5,149 |
02/05/24 | 8.28 | +0.24% | 4,165 |
Delayed Quote Xetra, May 08, 2024 at 04:36 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+82.32% | 75.07M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- APPH Stock